Evidence map›Paper›PMID 32376724›Full record

Trial reportJournal for immunotherapy of cancer2020

Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.

Lu Xie, Jie Xu, Xin Sun, Wei Guo, Jin Gu, Kuisheng Liu, Bingxin Zheng, Tingting Ren, Yi Huang, Xiaodong Tang and 5 more

Erratum issued 2 registry-linked trialsOpen access · goldAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 101 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 4 pooled it
10.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03359018 phase2completednot on this map

Apatinib Mesylate Plus Anti-PD1 Therapy (SHR-1210) in Locally Advanced, Unresectable or Metastatic Osteosarcoma(APFAO)Refractory to Chemotherapy : a Single Institution, Open-label, Phase 2 Trial

TypeinterventionalSponsorPeking University People's HospitalRan2018 to 2020Enrolled43ConditionsProgression-free Survival, Overall Survival, Clinical Benefit Rate, ToxicityArmsApatinib, SHR-1210
NCT04642664 phase2completednot on this map

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC): A Prospective Clinical Study

TypeinterventionalSponsorPeking Union Medical College HospitalRan2018 to 2021Enrolled22ConditionsBiliary Tract Cancer, Cholangiocarcinoma, Biomarker, Hepatobiliary NeoplasmArmsApatinib plus Camrelizumab
3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 4 syntheses or guidelines pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Review
  10. Review
  11. Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Lu XieMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Jie XuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xin SunMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Wei GuoMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China bonetumor@163.com.ORCID 0000-0002-4772-6592
Jin GuSurgical Oncology, Peking University Shougang Hospital, Beijing, China.
Kuisheng LiuMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Bingxin ZhengMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Tingting RenMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Yi HuangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Xiaodong TangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Taiqiang YanMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Rongli YangMusculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Kunkun SunPathology Department, Peking University People's Hospital, Beijing, China.
Danhua ShenPathology Department, Peking University People's Hospital, Beijing, China.
Yuan LiRadiology Department & Nuclear Medicine Department, Peking University People's Hospital, Beijing, China.
Peking University · CNPeking University Shougang Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundResults of our previous study showed high objective response but short-term activity of apatinib in advanced osteosarcoma. We aimed to investigate the activity of apatinib in combination with camrelizumab in patients with inoperable high-grade osteosarcoma progressing after chemotherapy.

methodsThis open-label, phase 2 trial was conducted at Peking University People's Hospital. We enrolled patients with advanced osteosarcoma progressed after chemotherapy. Patients received 500 mg apatinib orally once daily plus 200 mg camrelizumab by intravenous infusion every 2 weeks until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS) and clinical benefit rate at 6 months, which were based on RECIST V.1.1.

results43 patients were enrolled between January 25 and September 4, 2018. With median follow-up time of 48.3 (Q1, Q3, 30.6, 66.6) weeks, 13 (30.23%, 95% CI 17.2%, 40.1%) of 43 patients were progression free at 6 months and the 6-month PFS rate was 50.9% (95% CI 34.6%, 65.0%). Until final follow-up, the objective response rate was 20.9% (9/43) and two patients with durable disease control were observed. Patients with programmed cell death 1 ligand-1 (PD-L1) tumor proportion score ≥5% and pulmonary metastases tended to have a longer PFS in comparison to the others (p=0.004 and 0.017, respectively). Toxic effects led to dose reductions, or interruptions, or both in 24 (55.8%) of 43 patients and permanent discontinuation in 4 (9.3%) patients. There were no treatment-related deaths.

conclusionsAlthough the combination of apatinib and camrelizumab seemed to prolong PFS in comparison to single agent apatinib in treating advanced osteosarcoma, it did not reach the prespecified target of 6-month PFS of 60% or greater. Overexpression of PD-L1 and the presence of pulmonary metastases only were associated with longer PFS. TRIAL REGISTRATION NUMBER: NCT03359018.

Indexed as

Administration, OralAdolescentAdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBone NeoplasmsChildDisease ProgressionDrug Administration ScheduleFemaleFollow-Up StudiesHumansImmune Checkpoint InhibitorsInfusions, IntravenousMaleMiddle AgedAntibodies, Monoclonal, HumanizedapatinibcamrelizumabImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorProtein Kinase InhibitorsPyridinesbiomarkers, tumorclinical trials, phase II as topicdrug therapy, combinationimmunohistochemistrypediatrics

Identifiers

PMID32376724
PMCPMC7223462
OpenAlexW3021046581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.